Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo | AIDS Research and Therapy BioMed Central Open Access Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus HIV-1 in vitro and Simian Immunodeficiency virus SIV ex vivo Miriam C Poirier 1 Ofelia A Olivero1 Andrew W Hardy2 Genoveffa Franchini3 Jennifer P Borojerdi1 Vernon E Walker4 Dale M Walker4 and Gene M Shearer2 Address 1CDI Section LCBG CCR National Cancer Institute NIH Bethesda MD 20892 USA 2CMI Section EIB CCR National Cancer Institute NIH Bethesda MD 20892 USA 3AMRV CCR National Cancer Institute NIH Bethesda MD 20892 USA and 4University of Vermont Burlington VT 05405 USA Email Miriam C Poirier - poirierm@ Ofelia A Olivero - oliveroo@ Andrew W Hardy - Genoveffa Franchini - franchig@ Jennifer P Borojerdi - jborojerdi@ Vernon E Walker - vwalker@ Dale M Walker - bhcrg@ Gene M Shearer - shearerg@ Corresponding author Published 6 November 2009 Received 15 October 2009 Accepted 6 November 2009 AIDS Research and Therapy 2009 6 24 doi l742-6405-6-24 This article is available from http content 6 1 24 2009 Poirier et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background WR1065 is the free-thiol metabolite of the cytoprotective aminothiol amifostine which is used clinically at very high doses to protect patients against toxicity induced by radiation and chemotherapy. In an earlier study we briefly reported that the aminothiol WR1065 also inhibits HIV-1 replication in phytohemagglutinin PHA -stimulated human T-cell blasts TCBs infected in culture for 2 hr before WR1065 exposure. In this study we expanded the original observations to define the .
